IPO Year:
Exchange: NASDAQ
| Date | Price Target | Rating | Analyst |
|---|
BOULDER, Colo., Feb. 25, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or the "Company") announced today an update on its previously announced, planned dissolution and its process for distributing cash to its stockholders. Fresh Tracks plans on filing a Certificate of Dissolution with the Delaware Secretary of State, with dissolution effective February 28, 2025. As previously disclosed, on January 15, 2025, the Court of Chancery of the State of Delaware appointed Albert N. Marchio II as the custodian of the Company (the "Custodian"). In connection with the dissolution, the Custodian has authorized an initial distribution of $0.96 per share to holders, as of
In the news release, Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution, issued 27-Jan-2025 by Fresh Tracks Therapeutics, Inc. over PR Newswire, we are advised by the company that the reference to "...first quarter of 2024" at the end of the first paragraph was incorrectly stated and should read "...first quarter of 2025". The complete, corrected release follows: Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution BOULDER, Colo., Jan. 27, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("the Court") has g
BOULDER, Colo., Jan. 27, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("the Court") has granted the consent judgment agreed to by the Company in the case of David R. McAvoy versus Fresh Tracks, as a result of which the Court has appointed Albert N. Marchio II, Chief Executive Officer and Chief Financial Officer of Fresh Tracks, as the custodian of Fresh Tracks pursuant to 8 Del. C. § 226 with a directive to dissolve the Company and wind up its affairs. Fresh Tracks currently anticipates it will complete the dissolution and make a distribution of between $0.95 and $0.98 per
BOULDER, Colo., Dec. 6, 2024 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or "the Company") announced today that a Scheduling Order has been issued by the Court of Chancery of the State of Delaware ("the Court") setting a hearing date of January 17, 2025, for the Court to consider entry of a Consent Judgment agreed to by the Company in the case of David R. McAvoy versus Fresh Tracks. If the Consent Judgment is approved by the Court, a custodian will be appointed for Fresh Tracks pursuant to 8 Del. C. § 226 with a directive to dissolve the Company and windup its affairs. In accordance with a Court-approved scheduling order, Fresh Tracks has sent or will send to
BOULDER, Colo., June 17, 2024 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or the "Company") announced today that it has filed an Answer (the "Answer") to a Verified Petition for Appointment of a Custodian Pursuant to 8 Del. C. § 226 (the "Delaware Petition") that was filed with the Court of Chancery of the State of Delaware (the "Court") on May 17, 2024 by a stockholder and former General Counsel, Chief Compliance Officer, and Secretary of the Company, David R. McAvoy (the "Petitioner"). The Delaware Petition, to which the Answer outlines the Company is in overall agreement with, specifically requests that the Court issue an order appointing Albert N. Ma
Stockholders of record on January 11, 2024 who have not yet voted are encouraged to do so by 11:59 p.m. Eastern Time on February 14, 2024 BOULDER, Colo., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or the "Company") would like to remind its stockholders to vote their proxy ahead of the Company's upcoming special meeting of stockholders on February 15, 2024 (the "Special Meeting") at 12:00 p.m. Eastern Time to seek stockholder approval of the liquidation and dissolution of the Company (the "Dissolution") and the plan of liquidation and dissolution (the "Plan of Dissolution"). All stockholders of record of the Company's outstanding shares of
New record date expected to be January 11, 2024 Company intends to seek judicial dissolution if the liquidation and dissolution is not approved by Fresh Tracks' stockholders at new special meeting, which would reduce the amount of cash distributable to stockholders BOULDER, Colo., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX) ("Fresh Tracks" or the "Company") announced today plans to hold a new special meeting of stockholders on February 15, 2024 (the "Special Meeting") to seek stockholder approval of the liquidation and dissolution of the Company (the "Dissolution") and the plan of liquidation and dissolution (the "Plan of Dissolution"). As of today's r
BOULDER, Colo., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or the "Company") announced today that the Company's common stock was suspended from trading on The Nasdaq Capital Market at the open of business. Following the suspension, the Company's common stock now is quoted on the OTC Pink market under the same trading symbol, "FRTX." The Company has withdrawn its appeal of Nasdaq's determination to delist the Company's common stock, which will no longer trade on The Nasdaq Capital Market. Fresh Tracks intends to reconvene its special meeting of stockholders on December 27, 2023 and encourages all stockholders of record on October 17, 2023 w
BOULDER, Colo., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX) ("Fresh Tracks" or the "Company") announced today receipt of a notice from Nasdaq stating that the Company's common stock will be suspended from trading on The Nasdaq Capital Market at the open of business on December 19, 2023. Following the suspension, the Company expects its common stock to begin trading on an over-the-counter market. The Company anticipates disclosing further trading market information for its common stock once such information becomes available. As previously disclosed, on October 10, 2023, the Company received a notice from the Listing Qualifications Department (the "Staff
Meeting adjourned to December 27, 2023 at 10 a.m. MT Fresh Tracks encourages all stockholders of record on October 17, 2023 who have not yet voted to do so by 11:59 p.m. Eastern Time on December 26, 2023 Company intends to seek judicial dissolution if the liquidation and dissolution is not approved by Fresh Tracks' stockholders, which would reduce the amount of cash distributable to the stockholders BOULDER, Colo., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX) ("Fresh Tracks" or the "Company") announced today that its special meeting of stockholders (the "Special Meeting"), which was previously adjourned on November 16, 2023 and November 30, 2023, has b
15-12G - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)
10-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)
8-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)
8-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)
DEFA14A - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)
DEF 14A - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)
PRE 14A - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)
8-K - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)
S-8 POS - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)
S-8 POS - Fresh Tracks Therapeutics, Inc. (0000819050) (Filer)
SC 13D - Fresh Tracks Therapeutics, Inc. (0000819050) (Subject)
SC 13G/A - Fresh Tracks Therapeutics, Inc. (0000819050) (Subject)
SC 13G/A - Fresh Tracks Therapeutics, Inc. (0000819050) (Subject)
Reported positive topline results from SAD and MAD parts of Phase 1 study of lead DYRK1A inhibitor FRTX-02 in March 2023 Ongoing evaluation of strategic options to further develop FRTX-02 and maximize shareholder value Strengthened balance sheet with aggregate net proceeds of $6.6 million raised under an ATM program in March 2023 BOULDER, Colo., May 10, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the "Company" or "Fresh Tracks") (NASDAQ:FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today
Positive topline results from single and multiple ascending dose parts of the Phase 1 study of FRTX-02 support its continued development as a potential first-in-class, once-daily oral treatment for atopic dermatitis and/or other autoimmune diseases Continuing to evaluate strategic options to further develop FRTX-02 and maximize shareholder value Raised aggregate net proceeds of $6.6 million under ATM program in March 2023 BOULDER, Colo., March 30, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the "Company" or "Fresh Tracks") (NASDAQ:FRTX), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription the
In the news release, Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution, issued 27-Jan-2025 by Fresh Tracks Therapeutics, Inc. over PR Newswire, we are advised by the company that the reference to "...first quarter of 2024" at the end of the first paragraph was incorrectly stated and should read "...first quarter of 2025". The complete, corrected release follows: Fresh Tracks Therapeutics Announces Appointment of Custodian and Planned Distribution BOULDER, Colo., Jan. 27, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("the Court") has g
BOULDER, Colo., Jan. 27, 2025 /PRNewswire/ -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or "the Company") announced today that the Court of Chancery of the State of Delaware ("the Court") has granted the consent judgment agreed to by the Company in the case of David R. McAvoy versus Fresh Tracks, as a result of which the Court has appointed Albert N. Marchio II, Chief Executive Officer and Chief Financial Officer of Fresh Tracks, as the custodian of Fresh Tracks pursuant to 8 Del. C. § 226 with a directive to dissolve the Company and wind up its affairs. Fresh Tracks currently anticipates it will complete the dissolution and make a distribution of between $0.95 and $0.98 per
BOULDER, Colo., June 17, 2024 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (OTC:FRTX) ("Fresh Tracks" or the "Company") announced today that it has filed an Answer (the "Answer") to a Verified Petition for Appointment of a Custodian Pursuant to 8 Del. C. § 226 (the "Delaware Petition") that was filed with the Court of Chancery of the State of Delaware (the "Court") on May 17, 2024 by a stockholder and former General Counsel, Chief Compliance Officer, and Secretary of the Company, David R. McAvoy (the "Petitioner"). The Delaware Petition, to which the Answer outlines the Company is in overall agreement with, specifically requests that the Court issue an order appointing Albert N. Ma
BOULDER, Colo., Jan. 27, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. ("Fresh Tracks" or the "Company") (NASDAQ:FRTX), a clinical-stage pharmaceutical company aiming to disrupt existing treatment paradigms by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced its Board of Directors has appointed Andrew Sklawer, the Company's current President, as Chief Executive Officer (CEO), effective February 1, 2023. Mr. Sklawer will succeed Rob Brown, who has led the company as CEO since 2019 and is retiring. Mr. Brown will continue to serve as a non-executive member of the Board
4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)
4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)
4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)
4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)
4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)
4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)
4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)
4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)
4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)
4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)
4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)
4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)
4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)
4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)
4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)
4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)
4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)
4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)
4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)
4 - Fresh Tracks Therapeutics, Inc. (0000819050) (Issuer)